If your Crohn's disease is in remission and you still have cramping, loose stools, bloating or urgency, someone has probably said the word "IBS". It might be right. It might also be a way of ending a conversation that should have continued, because in Crohn's disease symptoms are an unreliable guide to what is happening inside the bowel.
The honest summary is this. IBS-like symptoms are common in Crohn's remission, more common than in ulcerative colitis, and they are real, distressing and treatable. But "IBS-like" describes how the symptoms feel, not what causes them. The cause can be leftover inflammation, a structural or surgical change, bile acids, bacterial overgrowth, or a genuinely overlapping IBS-type sensitivity, and the only way to know which is to measure things.
This guide covers how common these symptoms are, why Crohn's is harder to read than colitis, which tests rule out hidden inflammation (and where those tests fall short), the other explanations worth raising, what has been studied for management, and how to track so your next appointment produces a decision. It is deliberately separate from our page on ulcerative colitis symptoms in remission, because the two diseases behave differently here.
Can you have IBS-like symptoms when your Crohn's is in remission?
Yes. IBS-like symptoms in Crohn's remission are common, affecting somewhere between a quarter and a third of people depending on how remission is defined. They are associated with worse quality of life, and they are one of the most frequent reasons people feel "not really in remission" despite good test results.
The numbers come from two meta-analyzes from the same Leeds group. The 2012 analysis pooled 13 studies and 1,703 people and found that IBS-type symptoms were more common in Crohn's (46%) than in ulcerative colitis (36%), and that the odds were 4.39 times higher than in non-IBD controls even among people thought to be in remission (Halpin 2012). The 2020 update, with stricter inclusion rules and 27 studies, is the figure to remember.
| How remission was defined | Pooled prevalence of IBS-type symptoms |
|---|---|
| All IBD, any definition | 32.5% |
| Validated clinical activity index | 33.6% |
| Endoscopic remission | 23.5% |
| Histological remission | 25.8% |
| Crohn's disease only | 36.6% |
| Ulcerative colitis only | 28.7% |
Source: Fairbrass 2020. The studies varied a lot (heterogeneity was high), so treat these as ranges, not exact numbers.
"IBS-type" here means the person reported symptoms that meet a symptom-based IBS definition, usually the Rome criteria, which center on recurrent abdominal pain linked to bowel habit change. It is a description of symptom pattern. It does not mean a clinician has examined the person, looked for the Crohn's-specific causes below, and concluded that IBS is the explanation.
Is it IBS or hidden inflammation?
Symptoms alone usually cannot answer this. For a given person with Crohn's in remission and persistent symptoms, it is often unknown which it is until inflammation is measured. Published studies have not agreed, and the disagreement is instructive.
An Irish study of people judged to be in remission (Crohn's Disease Activity Index of 150 or below, CRP under 10) found that 37 of 62 with Crohn's, or 59.7%, met Rome II criteria for IBS. But their fecal calprotectin was significantly above normal, and was higher in those with IBS-type symptoms than in those without. The authors concluded that in most cases occult inflammation was likelier than coexisting IBS (Keohane 2010).
A Welsh cross-sectional study of 169 people with IBD found the opposite pattern. Calprotectin did not differ significantly between those in clinical remission with IBS-type symptoms (median 111 micrograms per gram) and those without (median 45.5). Among people with a normal calprotectin, 31% still had IBS-type symptoms. Those symptoms were more common in women (odds ratio 4.64) and linked to anxiety, and the authors concluded the two conditions are not mutually exclusive (Berrill 2013).
The most useful way to hold both studies is the four-group split proposed in a larger Leeds cohort of 378 patients, using a calprotectin cutoff of 250 micrograms per gram.
| Group | Symptoms | Calprotectin | What it suggests |
|---|---|---|---|
| True IBS-type symptoms | IBS-type | Below 250 | Symptoms without detectable mucosal inflammation |
| Quiescent IBD | None | Below 250 | Doing well on both counts |
| Occult inflammation | Normal activity index | 250 or above | Inflammation hiding behind a reassuring symptom score |
| Active IBD | Abnormal activity index | 250 or above | Symptoms and inflammation agree |
In that cohort, 57 of 206 people with Crohn's (27.7%) had true IBS-type symptoms, against 34 of 172 with ulcerative colitis (19.8%). Their quality of life was similar to people with active IBD, and well below the quiescent group (Gracie 2017).
Two points matter here. First, the four groups are only visible if someone has measured calprotectin. Without that number, "occult inflammation" and "true IBS-type symptoms" look identical from the outside. Second, a single threshold is a blunt tool, and the study repeated its analysis at 100 micrograms per gram and found a similar effect on psychological health and quality of life. Our post on whether fecal calprotectin can be normal with Crohn's disease goes into why the cutoff and the location of disease change what a result means.
Why are symptoms a worse guide in Crohn's than in colitis?
Symptoms track inflammation less closely in Crohn's, partly because Crohn's can sit anywhere from mouth to anus, partly because the bowel can be damaged without being inflamed, and partly because the standard symptom scores measure very little.
In a cohort of 356 people with Crohn's or ulcerative colitis, clinical disease activity was associated with mucosal inflammation in ulcerative colitis (odds ratio 3.36) but not in Crohn's (odds ratio 1.69, with a confidence interval that included no effect). Patient-reported symptoms had poor positive predictive values for mucosal inflammation in both diseases, and the authors concluded that symptoms and the Harvey-Bradshaw Index were poor predictors of mucosal inflammation in Crohn's. Psychological factors, particularly somatization, were associated with symptom reporting (Gracie 2016).
This is the point most often missed in forum advice. Two opposite errors both follow from it.
- "I feel fine, so I must be fine." Symptom scores can sit in the remission range while inflammation is present. That is the occult inflammation group above.
- "I feel awful, so my Crohn's must be flaring." Symptoms can be intense when the lining looks healed. That is the true IBS-type group, and the other causes in the next sections.
The Harvey-Bradshaw Index is a five-item score covering general well-being, abdominal pain, liquid stool count, abdominal mass and complications. It is a useful way to put your week on a standard scale, and our guide to what each Harvey-Bradshaw range means explains the bands. But it does not count bloating, urgency or the several other things people with IBS-like symptoms struggle with, and it was never designed to prove or disprove inflammation. Treat it as a way to describe symptoms consistently, not as a test of whether your bowel is healed.
What tests separate hidden inflammation from IBS-type symptoms?
The tests that matter are objective markers of inflammation, ordered from least to most invasive: blood and stool markers, imaging of the bowel wall, and endoscopy. Each has a blind spot, which is why the right answer is often more than one test.
International treat-to-target consensus (STRIDE-II) lists clinical remission and endoscopic healing as long-term targets in Crohn's, and symptom relief plus normalization of serum and fecal markers as short-term targets. It also says transmural healing in Crohn's is not a formal target but should be assessed as a measure of remission depth (Turner 2021). In plain terms, "I feel better" is one box, and it is not the only one.
| Test | What it can show | Where it falls short in Crohn's |
|---|---|---|
| Fecal calprotectin | Inflammation in the bowel lining, shed into stool | Less sensitive in Crohn's than colitis; weaker in small bowel disease; results vary with cutoff |
| CRP (blood) | Systemic inflammation | Often normal despite active Crohn's |
| Intestinal ultrasound or MR enterography | Bowel wall thickening, strictures, complications | Needs skilled operators or access; does not sample the lining |
| Ileocolonoscopy | Direct view of the lining and biopsies | Invasive; reaches the end of the ileum, not the whole small bowel |
| Capsule endoscopy | Small bowel lining | Not suitable if a stricture is suspected; specialist decision |
The meta-analysis of 19 studies and 2,499 symptomatic people found calprotectin had pooled sensitivity of 0.88 and specificity of 0.73 for endoscopic activity, and CRP had sensitivity of only 0.49 but specificity of 0.92. Calprotectin was more sensitive in ulcerative colitis than in Crohn's (Mosli 2015). So a raised calprotectin is a strong prompt to look further, and a normal CRP says very little on its own.
For small bowel disease the gap is clearer. In a study of 105 people with exclusively ileal Crohn's, calprotectin correlated only weakly with intestinal ultrasound (r = 0.502). A cutoff of 100 micrograms per gram gave 73.0% sensitivity and 71.4% specificity, and the authors concluded the two tests complement each other and that more studies on non-invasive testing in this location are needed (Paredes 2022). Our guide to intestinal ultrasound versus colonoscopy in Crohn's covers what imaging adds.
If you have the opposite pattern, a raised calprotectin but no symptoms, that is a different conversation, covered in our post on high calprotectin with no symptoms.
What else can mimic IBS in Crohn's remission?
Several Crohn's-specific problems produce loose stools, pain, bloating or urgency without active inflammation of the lining. None of these should be self-diagnosed. They are the questions worth bringing to your team before accepting IBS as the explanation.
Bile acid malabsorption. Bile acids are normally reabsorbed in the terminal ileum, which Crohn's commonly affects, and which is often resected. When they spill into the colon they can cause watery diarrhea and urgency that looks like IBS with diarrhea. In a post-hoc analysis of a clinical trial, an elevated serum bile acid marker (C4) was present in 37.1% of people with active Crohn's, was most often associated with isolated ileal disease, and persisted in many after treatment. Persistently elevated C4 was linked with worse stool-frequency outcomes but not with endoscopic remission. Even among people in endoscopic remission, those with elevated C4 had lower stool-frequency remission (36.0% versus 67.7%) (Battat 2025). It is a post-hoc analysis, but it is a clean illustration of how the lining can look healed while stool frequency stays high. See our bile acid malabsorption versus IBS guide for how it is distinguished.
Small intestinal bacterial overgrowth (SIBO). A meta-analysis of 29 studies found a pooled SIBO prevalence of 31.0% in IBD, 32.2% in Crohn's, and about five times the odds seen in healthy controls. Bloating, flatulence, prior abdominal surgery and stricturing or penetrating disease were associated with SIBO (Feng 2024). Breath testing has its own accuracy limits and treatment is a clinician decision, but if bloating and gas dominate your picture and you have had surgery or a stricture, it is a fair question. Our comparison of SIBO and IBS symptoms sets out the overlap.
Strictures and surgical change. Narrowing of the bowel can cause cramping, bloating and altered stool pattern after eating, and imaging, rather than a stool test, is how it is usually assessed. If you have had a resection, a different set of patterns applies, and our guide to a food and symptom diary after a Crohn's bowel resection is a better starting point.
Infection, medication and food intolerance. A recent gut infection, a new medication or supplement, and lactose or other carbohydrate intolerance can each produce loose stools in someone whose Crohn's is quiet. A new drug started around the time symptoms changed is worth noting in your log and mentioning to your prescriber. Do not stop or change anything yourself.
Clairop logs meals, symptoms and stool in seconds, then looks for the foods your gut reacts to, including reactions that land days later.
How does the gut-brain axis fit in?
Gut and mood influence each other in IBD, in both directions, and this is why IBS-type symptoms in remission are linked with anxiety and low mood without being "all in your head".
The 2020 meta-analysis found anxiety scores (weighted mean difference 2.5) and depression scores (standardized mean difference 0.64) significantly higher in people with IBS-type symptoms than in those without, and concluded that addressing psychological wellbeing might improve outcomes in this group (Fairbrass 2020). A Leeds cohort followed for at least two years found that baseline disease activity predicted later abnormal anxiety scores (hazard ratio 5.77), and that among people with quiescent IBD, abnormal anxiety scores at baseline predicted later steroid use or flare (hazard ratio 2.08) and escalation of therapy (hazard ratio 1.82) (Gracie 2018).
Read carefully, that means two things at once. Distress is more common when symptoms persist, and it is also associated with worse subsequent disease course. So the presence of anxiety is neither proof that your symptoms are functional nor a reason to be dismissed. It is a reason to treat both the bowel and the person. Our post on stress, anxiety and Crohn's flares goes further.
Clairop does not deliver therapy of any kind. If psychological support is part of your plan, that sits with your IBD team, a psychologist or your doctor.
What has been studied for managing IBS-like symptoms in Crohn's remission?
Evidence is limited, mostly small trials, and any approach should come after active inflammation has been checked. Two have published results worth knowing about.
A low FODMAP diet. In a single-blind randomized trial of 52 people with quiescent Crohn's or ulcerative colitis and persistent gut symptoms, 52% (14 of 27) on a 4-week low FODMAP diet reported adequate relief of gut symptoms versus 16% (4 of 25) on a control diet. The reduction in IBS severity score was larger on the low FODMAP diet but not statistically significant (p = 0.075), and quality of life scores were higher. Inflammatory markers did not differ, and the diet lowered the stool abundance of some bacteria thought to regulate immune response, including Bifidobacterium and Faecalibacterium prausnitzii (Cox 2020).
The practical reading is that a short, supervised low FODMAP trial may help some people in remission with persistent symptoms, that it is not a cure and not a long-term diet, and that it belongs with a dietitian who knows IBD and with a planned reintroduction. Restrictive diets also carry nutritional risks in a condition where weight and nutrient status already matter. See our guide on whether low FODMAP is good for Crohn's and the dietitian follow-up diary for how to structure the follow-up.
Osteopathy. In a small randomized study of 38 people with Crohn's in remission on infliximab, three sessions of osteopathy were followed by a significantly larger fall in IBS-like symptom severity than follow-up alone at some time points (Piche 2014). It is a small trial from one center, so it is worth knowing about, not a basis for a treatment decision.
Other medicines used for IBS (antispasmodics, bile acid binders, gut-directed psychological therapies) are discussed in IBS care, but this article does not cite Crohn's-specific trial evidence for them, so treat that as a conversation to have with your gastroenterologist rather than something this article endorses.
What should I track to make the next appointment useful?
Track the same few things every day for two to four weeks, in numbers where possible, and write down the dates of your last objective tests. The aim is a pattern your IBD team can act on, not a paragraph of adjectives.
A workable minimum looks like this.
- Stool count and form each day, plus any blood or mucus, and how many were liquid (this feeds the Harvey-Bradshaw Index).
- Urgency episodes and any accidents, since urgency is not captured by the usual scores.
- Night-time bowel movements or waking with pain. Night-time symptoms push toward inflammation and away from IBS.
- Pain location and timing, especially if it follows meals or eases after a bowel movement.
- Bloating and gas, with a rough severity, since these are the symptoms the scores skip.
- Fatigue and sleep. See our guide to Crohn's fatigue in remission for why this matters on its own.
- Meals, medication changes, infections, travel and stress, so that delayed patterns can be seen.
- Dates of your last calprotectin, CRP, imaging and colonoscopy, and where your disease is.
Clairop is an iPhone app built for this kind of daily log. It records bowel movements and meals, tests foods against symptoms over delay windows, calculates the Harvey-Bradshaw Index, and turns the entries into a one-page report for a GI visit, as described on how it works and the method page. It is a record and a communication aid, not a diagnostic tool, and nothing it shows can tell you whether you have inflammation. For the wider question of whether any symptom change is a real improvement, see how to measure IBS symptom improvement.
A worked example
Consider a hypothetical person, call her Maya, who has ileocolonic Crohn's and has been told she is in remission. She has had soft stools four or five times a day, bloating most evenings and cramps after meals for three months. Her last calprotectin was fourteen months ago and her last colonoscopy was two years ago.
A fair order of events, which her team would decide, might look like this. First, a log for three weeks showing stool counts, no blood, no night-time symptoms, and a pattern of worse evenings. Second, an up-to-date calprotectin and CRP. Third, depending on results and history, a discussion about imaging or endoscopy, and a question about bile acid malabsorption given ileal involvement. Fourth, only if inflammation is reasonably excluded, consideration of a supervised dietary approach and support for stress and sleep.
At no step does anyone decide "IBS" from the symptoms alone. The label, if it comes, arrives after the evidence. This is an illustration of reasoning, not a care plan for anyone.
How should I raise this with my IBD team?
Lead with what changed and what has and has not been measured, and ask for the next objective step rather than reassurance. A few sentences help.
- "My symptoms have been X for Y weeks, here is my log."
- "When was my inflammation last measured, and with which test?"
- "Could my symptoms still reflect inflammation that a stool test would miss, given where my Crohn's is?"
- "Has bile acid malabsorption, SIBO or a stricture been considered?"
- "If everything is reassuring, what is the plan for the symptoms themselves?"
Our list of questions to ask your doctor about Crohn's disease has more, and the IBS versus IBD guide explains how clinicians separate the two at diagnosis, which is the same logic in reverse.
Myths worth retiring
"If my calprotectin is normal, it is definitely IBS." Calprotectin is less sensitive in Crohn's than colitis and weaker in small bowel disease. A normal result lowers the odds of inflammation; it does not remove them.
"If I feel fine, my Crohn's is healed." Symptom scores can be in the remission range while inflammation is present, which is the occult group in the Leeds data.
"IBS-like symptoms mean it is stress." Mood is linked with these symptoms, but the link runs both ways and does not exclude inflammation, bile acids, SIBO or strictures.
"Having IBS-type symptoms means my Crohn's is getting worse." In the Leeds cohort they went with quality of life as poor as active IBD, but they were defined by the absence of raised calprotectin. That is the reason to test, not to assume either way.
"Ulcerative colitis and Crohn's work the same way here." They overlap, but Crohn's has a higher prevalence of IBS-type symptoms and a weaker symptom-to-inflammation link. In one Swedish cohort of 298 people with ulcerative colitis, only 18% of those in deep remission had IBS-like symptoms (Jonefjäll 2016), which shows how definitions change the picture.
"A low FODMAP diet will fix it." It helped some people in one trial, not others, and it is meant to be time-limited and supervised.
When should I see a doctor promptly?
Contact your IBD team promptly, rather than waiting for a routine slot, if any of the following appear.
- Blood in your stool, or black stools.
- Fever, night sweats or unexplained weight loss.
- Bowel movements or pain that wake you at night.
- Severe or worsening abdominal pain, or pain with repeated vomiting or a swollen abdomen (this may suggest a blockage and needs urgent care).
- Signs of anemia such as new breathlessness or marked tiredness.
- A persistent change from your usual pattern lasting more than a week or two.
- New symptoms starting after age 50, or a family history of bowel cancer, if you have not had them assessed.
This article is general information, not medical advice. Please do not use it to decide whether to start, stop or change any treatment.
The honest bottom line
IBS-like symptoms in Crohn's remission are common, affecting somewhere between a quarter and a third of people depending on how remission is defined. They are real, they reduce quality of life, and they respond to a mix of approaches. But in Crohn's, symptoms are a weak guide to inflammation, a normal stool test is less conclusive than people hope, and several non-IBS causes are specific to the disease. The best path is a short, dated record, an up-to-date objective picture of inflammation, a look at the Crohn's-specific alternatives, and only then a plan for the symptoms that remain.




